vida: extract claims from 2026-04-22-pmc11780016-radiology-ai-upskilling-study-2025

- Source: inbox/queue/2026-04-22-pmc11780016-radiology-ai-upskilling-study-2025.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ai-case-routing-prevents-threshold-calibration-skill-development.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: When AI determines which cases humans review, trainees never learn to calibrate what constitutes routine versus flagged cases
+confidence: experimental
+source: Academic Pathology Journal PMC11919318, pathology training commentary
+created: 2026-04-22
+title: AI-defined case routing prevents trainees from developing threshold-setting skills required for independent practice
+agent: vida
+sourced_from: health/2026-04-22-pmc11919318-pathology-ai-era-deskilling.md
+scope: structural
+sourcer: Academic Pathology Journal
+supports: ["never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling"]
+related: ["clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling"]
+---
+
+# AI-defined case routing prevents trainees from developing threshold-setting skills required for independent practice
+
+The paper notes that 'only human experts can revise the thresholds for case prioritization'—but this statement reveals a deeper problem: AI defines what humans see in the first place. When trainees are trained under an AI threshold system, they encounter only the cases the AI routes to them. This prevents development of a meta-skill beyond diagnostic competency: the ability to calibrate what's 'routine' versus 'flagged' is itself a clinical judgment skill. Trainees who never set thresholds themselves—because AI has always done it—lack the foundational experience to make these calibration decisions independently. This is distinct from diagnostic never-skilling: even if a trainee can correctly diagnose the cases they see, they may not develop the judgment to determine which cases require their attention in the first place. The threshold-setting skill requires exposure to the full case distribution, not just the AI-filtered subset.

domains/health/ai-cervical-cytology-screening-creates-never-skilling-through-routine-case-reduction.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Automation of routine cervical screening cases prevents trainees from developing the baseline diagnostic acumen required for independent practice
+confidence: experimental
+source: Academic Pathology Journal PMC11919318, commentary by pathology training experts
+created: 2026-04-22
+title: AI-integrated cervical cytology screening reduces trainee exposure to routine cases creating never-skilling risk for foundational pattern recognition skills
+agent: vida
+sourced_from: health/2026-04-22-pmc11919318-pathology-ai-era-deskilling.md
+scope: structural
+sourcer: Academic Pathology Journal
+supports: ["clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "never-skilling-distinct-from-deskilling-affects-trainees-not-experienced-physicians"]
+related: ["cytology-lab-consolidation-creates-never-skilling-pathway-through-80-percent-training-volume-destruction", "clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "never-skilling-distinct-from-deskilling-affects-trainees-not-experienced-physicians"]
+---
+
+# AI-integrated cervical cytology screening reduces trainee exposure to routine cases creating never-skilling risk for foundational pattern recognition skills
+
+AI automation in cervical cytology screening targets 'routine processes, such as initial screenings and pattern recognition in straightforward cases' for efficiency gains. However, these routine cases are precisely where trainees develop foundational pattern recognition skills. As AI handles large volumes of routine cervical screens, trainees see fewer cases across the full spectrum of findings. The paper notes this creates a risk where reduced case exposure prevents development of 'diagnostic acumen necessary for independent practice.' This is a structural never-skilling mechanism: the skill deficit won't manifest until trainees become independent practitioners facing edge cases without foundational grounding. The concern is particularly acute because AI may perform well in aggregate but fail on rare variants—exactly the cases humans need exposure to during training to handle them later. Unlike deskilling (where experienced practitioners lose existing skills), never-skilling affects trainees who never acquire the baseline competency in the first place.

domains/health/ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine.md

@@ -32,3 +32,10 @@ First comprehensive scoping review (literature through August 2025) confirms con
 **Source:** Oettl et al., Journal of Experimental Orthopaedics 2026
 
 Oettl et al. present the strongest available counter-argument to medical AI deskilling, arguing that AI will 'necessitate an evolution of the physician's role' toward augmentation rather than replacement. They propose three upskilling mechanisms: micro-learning at point of care, liberation from administrative burden, and performance floor standardization. However, the paper is primarily theoretical—all empirical evidence cited measures concurrent AI-assisted performance rather than post-training skill retention.
+
+
+## Challenging Evidence
+
+**Source:** Heudel et al., Insights into Imaging, 2025 (PMC11780016)
+
+Radiology residents using AI assistance showed resilience to large AI errors (>3 points), maintaining average errors around 2.75-2.88 even when AI was significantly wrong. This suggests physicians can detect and reject major AI errors during active use, which challenges the automation bias mechanism if physicians maintain critical evaluation capacity. However, this finding is limited to n=8 residents in a controlled setting and does not test whether this resilience persists under time pressure or after prolonged AI exposure.

domains/health/clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling.md

@@ -80,3 +80,10 @@ Oettl et al. 2026 explicitly distinguishes never-skilling from deskilling, notin
 **Source:** Oettl et al. 2026
 
 Oettl et al. explicitly distinguish never-skilling (trainees never developing foundational competencies) from deskilling (experienced physicians losing existing skills), noting that 'educators may lack expertise supervising AI use' which compounds the never-skilling risk. This adds population-specific mechanism detail to the three-mode framework.
+
+
+## Supporting Evidence
+
+**Source:** PMC11919318, Academic Pathology 2025
+
+Academic Pathology Journal commentary provides pathology-specific confirmation of never-skilling mechanism, noting that AI automation of routine cervical cytology screening reduces trainee exposure to foundational cases, preventing development of 'diagnostic acumen necessary for independent practice.' The paper explicitly distinguishes this from deskilling of experienced practitioners.

domains/health/divergence-human-ai-clinical-collaboration-enhance-or-degrade.md

@@ -62,3 +62,10 @@ Topics:
 **Source:** Oettl et al. 2026, Journal of Experimental Orthopaedics PMC12955832
 
 Oettl et al. 2026 provides the strongest articulation of the upskilling thesis, arguing that AI creates 'micro-learning at point of care' through review-confirm-override loops. However, the paper's own evidence base consists entirely of 'performance with AI present' studies (Heudel et al. showing 22% higher inter-rater agreement, COVID-19 detection achieving near-perfect accuracy with AI). No cited studies measure durable skill retention after AI training in a no-AI follow-up arm. The paper explicitly acknowledges: 'deskilling threat is real if trainees never develop foundational competencies' and 'further studies needed on surgical AI's long-term patient outcomes.' This represents the upskilling hypothesis at its strongest—and reveals that even its strongest proponents lack prospective longitudinal evidence.
+
+
+## Extending Evidence
+
+**Source:** Heudel et al., Insights into Imaging, 2025 (PMC11780016)
+
+Heudel et al. (2025) radiology study (n=8 residents, 150 chest X-rays) shows 22% improvement in inter-rater agreement (ICC-1: 0.665→0.813) and significant error reduction (p<0.001) WITH AI present. However, study design lacks post-training no-AI assessment, so it documents performance improvement during AI use, not durable skill retention. This is the primary empirical source cited by upskilling proponents (including Oettl 2026), but close reading reveals it only demonstrates AI-assisted performance, not independent upskilling. Residents showed 'resilience to AI errors above acceptability threshold' (maintaining ~2.75-2.88 error when AI made >3-point errors), suggesting some critical evaluation capacity persists during AI use.

domains/health/federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level.md

@@ -16,3 +16,10 @@ related: ["generic-digital-health-deployment-reproduces-existing-disparities-by-
 # Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics
 
 The Medicare GLP-1 Bridge program demonstrates that the GLP-1 access inversion operates at the program design level, not just the market level. While the program was designed to 'expand access' to GLP-1 obesity medications, its legal architecture—required because Medicare is statutorily prohibited from covering weight-loss drugs—places it outside standard Part D benefit structures. This design choice has the consequence of making Low-Income Subsidy (LIS) protections inapplicable, creating a $50 copay barrier for the lowest-income beneficiaries. The mechanism is not market failure or insurance company gatekeeping, but federal program architecture itself. The program's eligibility criteria are inclusive (BMI ≥35 alone, or ≥27 with clinical criteria), but the cost-sharing structure excludes the most access-constrained population. This reveals that access inversions can be encoded into the legal and administrative structure of interventions designed to improve equity, suggesting that coverage expansion and coverage restriction can occur simultaneously through different layers of program design. The pattern indicates that addressing GLP-1 access disparities requires attention to program architecture, not just coverage mandates.
+
+
+## Supporting Evidence
+
+**Source:** KFF 2025 poll demographic breakdown
+
+Age 65+ adults show only 9% GLP-1 usage compared to 22% for ages 50-64, directly reflecting Medicare's statutory exclusion of weight-loss drugs. This creates a sharp discontinuity at the Medicare eligibility threshold despite this population having the highest obesity burden and worst health outcomes. The demographic pattern confirms that structural coverage exclusions, not clinical need, determine access.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -39,3 +39,10 @@ The Medicaid population has the highest obesity burden (40% of adults, 25% of ch
 **Source:** KFF analysis of Medicare GLP-1 Bridge program (April 2026)
 
 The Medicare GLP-1 Bridge program provides concrete evidence that the access inversion operates through federal program architecture, not just market dynamics. The program's legal structure—required because Medicare is statutorily prohibited from covering weight-loss drugs—places the benefit outside Part D cost-sharing structures, making Low-Income Subsidy (LIS) protections inapplicable. This creates a $50 copay barrier for the lowest-income beneficiaries despite inclusive eligibility criteria. The mechanism is program design itself: coverage expansion and coverage restriction occurring simultaneously through different layers of administrative architecture.
+
+
+## Supporting Evidence
+
+**Source:** KFF 2025 national poll, N=1,309 adults
+
+KFF national poll finds only 23% of obese/overweight adults currently taking GLP-1s, meaning 77% of the eligible population is not accessing treatment despite drug availability. Among current users, 56% report difficulty affording medications, and 27% of insured users paid full cost out-of-pocket. Cost-driven discontinuation (14%) rivals side effect discontinuation (13%), demonstrating affordability as a primary access barrier.

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -32,3 +32,10 @@ As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obes
 **Source:** KFF analysis of Medicare GLP-1 Bridge program (April 2026)
 
 The Medicare GLP-1 Bridge program demonstrates that access inversion operates at the federal program design level, not just state-level coverage decisions. The program's LIS exclusion means that even a federal coverage expansion structurally excludes the lowest-income Medicare beneficiaries, adding a new layer to the systematic inversion pattern: legal architecture can override equity intentions.
+
+
+## Supporting Evidence
+
+**Source:** KFF 2025 poll condition-specific usage
+
+Among patients with diagnosed conditions showing clear clinical benefit, uptake remains limited: 45% of diabetes patients and 29% of heart disease patients currently using GLP-1s. Even in populations with established medical indication and likely insurance coverage, majority non-uptake persists. The 56% affordability difficulty rate among current users demonstrates cost barriers operate even after initial access is achieved.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -10,14 +10,16 @@ agent: vida
 scope: structural
 sourcer: BCBS Health Institute
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]]"]
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
-reweave_edges:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "divergence-glp1-economics-chronic-cost-vs-low-persistence"]
+reweave_edges: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09"]
 ---
 
 # GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
 
-Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.
+Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.
+
+## Extending Evidence
+
+**Source:** KFF 2025 poll
+
+Cost is a major driver of discontinuation: 14% of former GLP-1 users stopped due to cost, matching the 13% who stopped due to side effects. Among current users, 56% report difficulty affording medications, suggesting cost pressure operates throughout the treatment duration, not just at initiation. The 27% of insured users paying full out-of-pocket cost indicates insurance coverage gaps contribute to persistence failures.

domains/health/never-skilling-distinct-from-deskilling-affects-trainees-not-experienced-physicians.md

@@ -16,3 +16,10 @@ related: ["cytology-lab-consolidation-creates-never-skilling-pathway-through-80-
 # Never-skilling is mechanistically distinct from deskilling because it affects trainees who lack baseline competency rather than experienced physicians losing existing skills
 
 Oettl et al. explicitly distinguish 'never-skilling' from deskilling as separate mechanisms with different populations and dynamics. Deskilling affects experienced physicians who have baseline competency and lose it through AI reliance. Never-skilling affects trainees who never develop foundational competencies because AI is present from the start of their training. The paper states: 'Deskilling threat is real if trainees never develop foundational competencies' and notes that 'educators may lack expertise supervising AI use.' This distinction is critical because: (1) never-skilling is detection-resistant (no baseline to compare against), (2) it's unrecoverable (can't restore skills that were never built), and (3) it requires different interventions (curriculum redesign vs. retraining). The cytology lab consolidation example in the KB shows this pathway: 80% training volume destruction means residents never get enough cases to develop competency, regardless of whether AI helps or hurts on individual cases. This is a structural training pipeline problem, not an individual skill degradation problem.
+
+
+## Supporting Evidence
+
+**Source:** PMC11919318, Academic Pathology 2025
+
+Pathology training experts confirm the trainee-specific nature of never-skilling in cervical cytology: as AI handles routine screening cases, trainees see fewer cases across the full diagnostic spectrum, preventing baseline competency development. The concern is that skill deficits won't manifest until independent practice.

domains/health/never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling.md

@@ -30,3 +30,10 @@ Cytology lab consolidation demonstrates unrecoverability: 37 labs closed (45 to
 **Source:** Oettl et al., Journal of Experimental Orthopaedics 2026
 
 Oettl et al. explicitly acknowledge that never-skilling is a genuine threat if 'trainees never develop foundational competencies' and note that 'educators may lack expertise supervising AI use,' compounding the detection problem. This supports the claim that never-skilling is structurally harder to address than deskilling.
+
+
+## Extending Evidence
+
+**Source:** PMC11919318, Academic Pathology 2025
+
+The threshold calibration skill deficit adds a detection-resistance mechanism: trainees may appear competent on the cases they see (AI-routed subset) but lack the judgment to determine which cases require attention in the first place. This meta-skill deficit only becomes visible when trainees must independently triage cases without AI routing.

domains/internet-finance/anprm-comment-volume-signals-bipartisan-political-pressure-on-cftc-rulemaking.md

@@ -114,3 +114,10 @@ Tribal gaming operators represent a politically powerful coalition with bipartis
 **Source:** Norton Rose Fulbright ANPRM analysis, April 21 2026
 
 Norton Rose provides detailed comment composition breakdown: 800+ total submissions as of April 19, with only 19 filed before April 2. Sharp surge after April 2 coincides with CFTC suing three states, raising public visibility. Submitters include state gaming commissions, tribal gaming operators, prediction market operators (Kalshi, Polymarket, ProphetX), law firms, academics (Seton Hall), and private retail citizens. Dominant tonal split: institutional skews negative, industry skews self-regulatory positive, retail skews skeptical. The retail citizen comment surge (predominantly skeptical) after April 2 is a new dynamic showing genuine public engagement from people who see prediction markets as gambling.
+
+
+## Extending Evidence
+
+**Source:** IGA Chairman David Bean, CNIGA Chairman James Siva, Yogonet April 2026
+
+Tribal gaming operators filed ANPRM comments representing a $40B+ industry with federal treaty protections under IGRA. Indian Gaming Association and California Nations Indian Gaming Association characterized CFTC preemption as existential threat to tribal exclusivity. This adds a politically powerful coalition with bipartisan congressional access that is distinct from state AG opposition.

domains/internet-finance/cftc-multi-state-litigation-represents-qualitative-shift-from-regulatory-drafting-to-active-jurisdictional-defense.md

@@ -65,3 +65,10 @@ Norton Rose analysis documents that the sharp surge in ANPRM comments after Apri
 **Source:** MultiState, March 2026
 
 Curtis-Schiff bill filed three weeks after Arizona criminal charges represents coordination between legislative and enforcement pathways. Bipartisan Senate sponsorship (Curtis R-Utah, Schiff D-California) breaks the partisan framing identified in Session 20, elevating legislative risk above court-based jurisdictional defense.
+
+
+## Extending Evidence
+
+**Source:** Pueblo of Laguna ANPRM comments, Yogonet April 2026
+
+Tribal gaming opposition creates a second litigation front beyond state AGs. Tribes have standing to challenge CFTC preemption based on IGRA federal law, not just state gambling law. Pueblo of Laguna and other tribal nations cited revenue losses from unregulated prediction market activity in ANPRM comments.

domains/internet-finance/prediction-market-regulatory-legitimacy-creates-both-opportunity-and-existential-risk-for-decision-markets.md

@@ -106,3 +106,10 @@ ProphetX's compliance-first strategy (filing DCM/DCO applications before ANPRM p
 **Source:** ProphetX CFTC ANPRM comments, April 2026
 
 ProphetX's Section 4(c) proposal represents a new regulatory strategy: purpose-built compliance rather than operate-and-litigate. This creates a third path beyond Kalshi's litigation strategy and Polymarket's offshore-then-acquire approach—building specifically for regulatory engagement from inception.
+
+
+## Extending Evidence
+
+**Source:** Tribal gaming ANPRM comments, April 2026
+
+Tribal gaming opposition introduces a new dimension of regulatory risk: federal preemption that solves state gambling law conflicts simultaneously destroys federal tribal gaming protections under IGRA. This creates congressional pressure for a legislative fix that regulatory approaches cannot provide, potentially forcing CFTC to narrow its preemption claims or face legislative override.

domains/space-development/commercial-station-timeline-compression-tightens-iss-succession-window.md

@@ -10,8 +10,16 @@ agent: astra
 scope: structural
 sourcer: Payload Space
 related_claims: ["[[commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030]]"]
+related: ["commercial-station-timeline-compression-tightens-iss-succession-window", "commercial-station-development-timelines-miss-iss-2030-retirement-deadline-as-of-march-2026", "the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit", "commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030", "Vast is building the first commercial space station with Haven-1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s"]
 ---
 
 # Haven-1 slip to Q1 2027 compresses the commercial station succession timeline against ISS deorbit around 2030
 
 Haven-1 was originally targeted for May 2026 launch as the first commercial standalone space station. The slip to Q1 2027 represents a full-year delay. With ISS deorbit planned for approximately 2030, this reduces the window for commercial stations to achieve operational maturity, validate capabilities, and transfer institutional knowledge from ISS operations. Haven-1's three-year planned lifespan means it would operate only until 2030—the same timeframe as ISS deorbit. This creates timeline compression where commercial succession must happen with minimal operational overlap rather than the gradual transition originally envisioned. The delay pattern (full year slip from initial target) also suggests commercial station development timelines may be more optimistic than realistic, further tightening the succession window.
+
+
+## Supporting Evidence
+
+**Source:** NASASpaceFlight, April 2026
+
+Haven-1 launch delayed from May 2026 target to Q1 2027, further compressing the timeline for commercial stations to achieve operational status before ISS retirement in 2030. With the 1-year overlap mandate, Haven-1 must be operational by 2031 at the latest to fulfill the succession requirement.

entities/internet-finance/pueblo-of-laguna.md

@@ -1,23 +1,13 @@
 # Pueblo of Laguna
 
-**Type:** Tribal Nation / Gaming Operator  
-**Domain:** Internet Finance (Regulatory Stakeholder)  
-**Status:** Active
+**Type:** Tribal Nation  
+**Domain:** Internet Finance  
+**Status:** Active  
 
 ## Overview
 
-Pueblo of Laguna is a federally recognized Native American tribe operating gaming facilities under the Indian Gaming Regulatory Act (IGRA). The tribe has filed regulatory comments opposing CFTC prediction market preemption.
+Pueblo of Laguna is a federally recognized tribal nation that operates gaming facilities under the Indian Gaming Regulatory Act (IGRA). The tribe has participated in regulatory proceedings concerning prediction markets and their impact on tribal gaming exclusivity.
 
 ## Timeline
 
-- **2026-04-20** — Filed ANPRM comments with CFTC citing revenue losses from unregulated prediction market activity threatening tribal gaming exclusivity
-
-## Regulatory Position
-
-Pueblo of Laguna opposes CFTC classification of sports betting as event contracts/swaps, arguing that federal preemption of state gambling laws undermines the state-tribal compact framework established under IGRA.
-
-## Related Entities
-
-- [[indian-gaming-association]]
-- [[california-nations-indian-gaming-association]]
-- [[cftc]]
+- **2026-04-20** — Filed ANPRM comments with CFTC citing revenue losses from unregulated prediction market activity threatening tribal gaming exclusivity

entities/space-development/change-7.md

@@ -4,39 +4,42 @@ entity_type: mission
 name: Chang'e-7
 domain: space-development
 status: active
-operator: China National Space Administration
-launch_vehicle: Long March 5
-launch_site: Wenchang Spaceport
-target: Lunar south pole (near Shackleton crater)
+parent_organization: China National Space Administration
 ---
 
 # Chang'e-7
 
-Chang'e-7 is China's lunar south pole exploration mission designed to search for water-ice deposits in permanently shadowed craters. The mission consists of four elements: an orbiter, lander, rover, and a unique hopping probe.
+Chang'e-7 is a Chinese lunar exploration mission targeting the lunar south pole to search for water-ice deposits in permanently shadowed craters. The mission consists of an orbiter, lander, rover, and a unique hopping probe designed to operate in extreme darkness and cold.
 
 ## Mission Architecture
 
-**Hopping Probe**: The mission's key innovation is a hopping probe equipped with the Lunar soil Water Molecule Analyzer (LUWA), designed to operate in the extreme darkness and cold of permanently shadowed regions (PSRs). This architecture enables direct investigation of areas that wheeled rovers cannot access.
+**Launch Vehicle:** Long March 5
 
-**Scientific Payload**: 18 scientific instruments distributed across all mission elements, including:
-- Lander: cameras, seismographs, Italian laser reflector
-- Rover: panoramic imaging equipment
-- Hopping probe: LUWA for water ice detection
+**Mission Elements:**
+- Orbiter
+- Lander with cameras, seismographs, and Italian laser reflector
+- Rover with panoramic imaging equipment
+- Hopping probe with Lunar soil Water Molecule Analyzer (LUWA)
 
-## Mission Objectives
+**Total Instruments:** 18 scientific instruments across all elements
 
-Primary objective is to confirm water ice at accessible concentrations to validate the ISRU pathway for lunar south pole operations, demonstrating that future missions can:
-- Extract drinking water
-- Produce oxygen
-- Generate rocket propellant from local resources
+**Target Location:** Near Shackleton crater at the lunar south pole
 
-## Timeline
+## Key Innovation
 
-- **2026-04-09** — Mission hardware arrived at Wenchang spaceport for final launch preparations
-- **2026-08 (projected)** — Target launch window in second half of 2026
+The hopping probe represents a novel architecture for investigating permanently shadowed regions (PSRs). Unlike rovers that cannot enter PSRs due to extreme cold and lack of solar power, the hopping probe can physically enter these regions to conduct direct in-situ measurements of water ice concentration.
+
+## Scientific Objectives
+
+- Confirm presence and concentration of water-ice deposits in permanently shadowed craters
+- Validate ISRU pathway for lunar south pole operations
+- Demonstrate that future missions can extract drinking water, produce oxygen, and generate rocket propellant from local resources
 
 ## Strategic Context
 
-Chang'e-7 may reach the lunar south pole before NASA's VIPER rover, which faces delays due to New Glenn/Blue Moon dependencies. The hopping probe's ability to enter PSRs represents a more capable investigation architecture than VIPER's rover-only design.
+Chang'e-7 may reach the lunar south pole and characterize water ice before NASA's VIPER rover, which faces timeline delays. If successful, China would establish the first confirmed evidence base for lunar water ice accessibility, potentially creating leverage in cislunar resource governance discussions.
 
-Builds on Chang'e-6's successful far-side lunar sample return (2024), demonstrating sustained operational cadence in China's lunar exploration program.
+## Timeline
+
+- **2026-04-09** — Spacecraft arrived at Wenchang spaceport for final launch preparations
+- **2026-08 (projected)** — Target launch window in second half of 2026

entities/space-development/starbase-pad-2.md

@@ -0,0 +1,36 @@
+# Starbase Pad 2
+
+**Type:** Orbital launch complex
+**Operator:** SpaceX
+**Location:** Boca Chica, Texas
+**Status:** Operational (refinements complete as of April 2026)
+**First launch:** Starship Flight 12 (targeting early May 2026)
+
+## Overview
+
+Starbase Pad 2 is SpaceX's second orbital launch complex at Boca Chica, Texas. Its completion doubles Starship launch capacity at the Starbase facility, enabling higher cadence operations critical to Starship's reuse economics model.
+
+## Operational Significance
+
+The two-pad configuration allows SpaceX to:
+- Conduct vehicle processing and launch operations in parallel
+- Reduce turnaround time between launches
+- Increase annual launch capacity for Starship
+- Test and iterate on vehicle designs more rapidly
+
+With 44 Starship missions planned for 2026, the second pad is essential infrastructure for achieving the launch cadence required to validate reuse economics.
+
+## Timeline
+
+- **2026-04** — Pad refinements completed
+- **2026-05** (target) — First launch: Starship Flight 12 (V3)
+
+## Related Infrastructure
+
+- Starbase Pad 1 (original orbital launch complex)
+- Starship V3
+- Boca Chica production facility
+
+## Sources
+
+- NASASpaceFlight.com, April 2026

entities/space-development/starship-flight-12.md

@@ -0,0 +1,37 @@
+# Starship Flight 12
+
+**Type:** Test flight  
+**Vehicle:** Starship V3 (Ship 39 upper stage, Booster 19 Super Heavy)  
+**Launch Site:** Starbase Pad 2, Boca Chica, Texas  
+**Status:** Pre-launch (static fires complete as of April 2026)  
+**Target Date:** Early May 2026  
+
+## Overview
+
+Starship Flight 12 represents the first flight of the V3 generation Starship and the inaugural launch from SpaceX's second orbital launch pad at Starbase. The mission follows successful full-duration static fire tests of both Ship 39 and Booster 19 in April 2026.
+
+## Vehicle Configuration
+
+- **Upper Stage:** Ship 39 (Starship V3)
+- **Booster:** Booster 19 (Super Heavy with 33 Raptor 3 engines)
+- **Key V3 Features:**
+  - Raptor 3 engines with no external plumbing
+  - Increased propellant capacity
+  - Target payload capacity: 100+ tonnes to LEO
+
+## Development Timeline
+
+- **March 9, 2026:** Initial target date
+- **April 4, 2026:** Revised target date
+- **April 2026:** Both vehicles complete full-duration static fires
+- **Early May 2026:** Current launch target
+
+## Significance
+
+Flight 12 is critical for validating V3's performance claims, particularly the 100+ tonne payload capacity and reuse economics enabled by Raptor 3's simplified design. The mission will provide the first real data on whether V3 achieves the cost reduction trajectory toward the $500/kg threshold.
+
+The launch from Pad 2 demonstrates SpaceX's dual-pad capability at Starbase, doubling potential launch cadence for the 44 Starship missions planned in 2026.
+
+## Timeline
+
+- **2026-04-22** — Ship 39 and Booster 19 complete full-duration static fires; Flight 12 targeting early May 2026 launch from Pad 2

entities/space-development/starship-v3.md

@@ -0,0 +1,47 @@
+# Starship V3
+
+**Type:** Launch vehicle (next-generation heavy-lift)
+**Developer:** SpaceX
+**Status:** Pre-flight (static fire testing complete as of April 2026)
+**First flight:** Flight 12, targeting early May 2026
+**Launch site:** Starbase Pad 2, Boca Chica, Texas
+
+## Overview
+
+Starship V3 is the third-generation design of SpaceX's fully reusable super heavy-lift launch system. It represents a clean-sheet redesign from V2, featuring Raptor 3 engines, increased propellant capacity, and targeting 100+ tonnes payload to LEO.
+
+## Key Features
+
+- **Raptor 3 engines:** Simplified design with no external plumbing, reducing failure points and manufacturing complexity
+- **Increased propellant capacity:** Enables higher payload mass and mission flexibility
+- **Target payload:** 100+ tonnes to LEO (up from V2's demonstrated capacity)
+- **Super Heavy Booster 19:** 33 Raptor 3 engines
+- **Ship 39:** Upper stage with Raptor 3 engines
+
+## Development Status
+
+V3 development appears more mature than V2 at equivalent milestones. Both Ship 39 and Booster 19 completed full-duration static fires without reported anomalies, contrasting with V2's multiple static fire issues during development.
+
+## Infrastructure
+
+Flight 12 will be the first Starship launch from Pad 2 at Starbase, SpaceX's second orbital launch complex. The two-pad configuration doubles potential launch cadence at Boca Chica.
+
+## Timeline
+
+- **2025-10-13** — Flight 11 (final V2 flight) completed with ocean splashdown
+- **2026-04** — Ship 39 and Booster 19 complete full static fires
+- **2026-05** (target) — Flight 12, first V3 launch from Pad 2
+
+## Significance
+
+V3 performance data will provide the first empirical validation of Starship's path toward sub-$100/kg launch costs. The Raptor 3 simplification and increased payload capacity are critical enablers for the reuse economics model underlying SpaceX's cost trajectory projections.
+
+## Related Systems
+
+- Starship V2 (predecessor)
+- Raptor 3 engine
+- Starbase Pad 2
+
+## Sources
+
+- NASASpaceFlight.com, April 2026